La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

D. Western Therapeutics Institute Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Yuichi Hidaka

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	15.8yrs
Proprietà del CEO	7.8%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	10.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

May 23

AMMINISTRATORE DELEGATO

Yuichi Hidaka (51 yo)

15.8yrs

Mandato

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Yuichi Hidaka	President	15.8yrs	Nessun dato	7.82% ¥ 222.1m
Sayako Matsubara	CFO & Director	1.5yrs	Nessun dato	0.015% ¥ 425.5k
Yoshiyuki Yamakawa	Independent Outside Director	14.5yrs	Nessun dato	0.048% ¥ 1.4m
Eisaku Nakamura	Independent Outside Director	6.4yrs	Nessun dato	0.00027% ¥ 7.7k
Masaaki Suzuki	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Tasuku Honjyo	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Masato Shibuya	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Arata Uemura	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anthony Means	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Walter Chazin	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Yasuhiko Ito	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Yasumi Uchida	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

10.5yrs

Durata media

56.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4576 è composto da personale esperto e esperto (durata media dell'incarico 10.4 anni).

D. Western Therapeutics Institute Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

Recent updates

D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023)

New major risk - Share price stability

New minor risk - Shareholder dilution

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023)

New minor risk - Shareholder dilution

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022)

New minor risk - Share price stability

D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022)

D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Insufficient new directors

Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021)

D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.

D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021

D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020

D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media

Età media